COMMUNIQUÉS West-GlobeNewswire

Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®
29/11/2018
Oasmia Pharmaceutical AB (Nasdaq: OASM) today announce that the company has signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea. Technology and know-how are [...]
AbbVie sponsored REACH study for the use of Genedrive HCV assay in pharmacies
29/11/2018
For release: 29 November genedrive plc ("genedrive" or the "Company") AbbVie sponsored REACH study for the use of Genedrive HCV assay in pharmacies genedrive plc (AIM: GDR), the near patient molecular diagnostics [...]
ObsEva SA to Host R&D Investor Day December 7, 2018
29/11/2018
Geneva, Switzerland and Boston, MA – November 29, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for serious [...]
Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.
29/11/2018
This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn's, Bronchopulmonary dysplasia, Epilepsy and Stroke Amsterdam, The Netherlands - 29 [...]
Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
29/11/2018
Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free at two years[1] Young [...]
Biocartis Group NV: Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results
29/11/2018
PRESS RELEASE: 29 November 2018, 07:00 CET Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results Mechelen, Belgium, 29 November 2018 - Biocartis Group NV (the 'Company' or ' [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
29/11/2018
Regulated information Gosselies, Belgium, 29 November 2018, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
29/11/2018
Information réglementée Gosselies, Belgique, le 29 novembre 2018, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins [...]
Revive Therapeutics Announces Results for the Three Months Ended September 30, 2018
29/11/2018
TORONTO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) (“Revive” or the “Company”) , a specialty cannabis company focused on the research, development and [...]
L’autotest de dépistage du VIH INSTI obtient le statut de préqualification de l’OMS pour le test à domicile
29/11/2018
L’autotest de dépistage du VIH INSTI qui a récemment obtenu la préqualification de l’OMS impose sa marque alors qu’il s’étend à de nouveaux marchés VANCOUVER, Colombie-Britannique, 29 nov. 2018 (GLOBE NEWSWIRE) -- [...]
aTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
29/11/2018
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
29/11/2018
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Telix and Nihon Medi-Physics to Collaborate on Actinium Renal Cancer Therapeutics
29/11/2018
MELBOURNE, Australia, KYOTO, Japan and TOKYO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of [...]
Geron to Host Analyst and Investor Event on December 10, 2018
28/11/2018
MENLO PARK, Calif., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company’s analyst and investor event will take place in New York, N.Y., on Monday, December 10, 2018. [...]
Radient Technologies Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
28/11/2018
EDMONTON, Alberta, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI) announced today that it has released its financial results for the second fiscal quarter [...]
Imagin Medical Comments on Recent Promotional Activity Pursuant to OTC Markets Request
28/11/2018
VANCOUVER, British Columbia and BOSTON, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) wishes to make the following [...]
Retrophin to Present at the BMO Prescriptions for Success Healthcare Conference
28/11/2018
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the BMO 2018 Prescriptions for Success Healthcare Conference in [...]
Oasmia intends to issue notice to an extraordinary general meeting at the request of a shareholder and announces that it is subject to legal proceedings with a major shareholder concerning the company’s warrants 2018/2019
28/11/2018
Oasmia Pharmaceutical AB (publ) (“Oasmia”) hereby announces that Oasmia’s largest shareholder, Arwidsro Investment AB and Per Arwidson (together “Arwidsro”), on the basis of Chapter 7 Section 13 of the Swedish Companies [...]
Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability
28/11/2018
Almost 90% ocular delivery success with high-precision smart micro-dosing sets new benchmark for topical instillation to the eye NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced [...]

Pages